Parameter | PsO cohort (n=5181) | PsA cohort (n=1380) | AS cohort (n=794) |
Gender | |||
Female (n, %) | 1743 (33.6%) | 742 (53.8%) | 265 (33.4%) |
Male (n, %) | 3438 (66.4%) | 638 (46.2%) | 529 (66.6%) |
Age, years, mean (SD) | 45.7 (13.3) | 48.8 (12.0) | 42.4 (12.3) |
Prior exposure (with inadequate response) to TNF antagonists, n (%) | NA* | 435 (31.5%) | 227 (28.6%) |
Prior exposure (with inadequate response) to biological therapy, n (%) | 784 (15.1%) | NA | NA |
Current smoker at BL, n (%) | 1585 (30.6%) | 262 (19%) | 234 (30%) |
Prior azathioprine use, n (%) | 7 (0.1%) | 15 (1.1%) | 1 (0.1%) |
*Specific data on prior TNF antagonist exposure is not available for the PSO cohort however 784 (15.1%) of these patients had a previous exposure with inadequate response to biologic therapies including TNF antagonists.
AS, ankylosing spondylitis; BL, baseline; CD, Crohn’s disease; PsA, psoriatic arthritis; PsO, psoriasis; UC, ulcerative colitis.